BioMedNewsBreaks – Brain Scientific Inc. (BRSF) Secures FDA Clearance for Next-Gen NeuroCap(TM)

March 9, 2021 11:06:02

Brain Scientific (OTCQB: BRSF), a neurology focused medical device and software company, today announced its receipt of U.S. Food and Drug Administration (“FDA”) 510(k) clearance for its next-generation NeuroCap(TM) device. NeuroCap is an advanced electroencephalogram (“EEG”) electrode array used to obtain rapid EEGs in routine clinical and research settings where recording of STAT EEGs is desired. “We are constantly working on new products for the EEG market. In the new version of NeuroCap, we added velcro strips for better adhesion. We also expanded the size range by adding an XS (extra small) size,” said Irina Nazarova, marketing director at Brain Scientific. “And now this device is designed for broader use — in addition to intensive care units and ERs.”

To view the full press release, visit

About Brain Scientific

Brain Scientific is a commercial-stage health care company with two FDA-cleared products, providing next-gen solutions to the neurology market. The company’s smart diagnostic devices and sensors simplify administration, shorten scan time and cut costs, allowing clinicians to make rapid decisions remotely and bridge the widening gap in access to neurological care. To learn more about the company’s corporate strategy, devices or for investor relations, visit

NOTE TO INVESTORS: The latest news and updates relating to BRSF are available in the company’s newsroom at

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published:

BioMedWire (BMW)
San Francisco, California
415.949.5050 Office

BioMedWire is part of the InvestorBrandNetwork